Evidence map›Paper›PMID 40501985›Full record

ArticlebioRxiv : the preprint server for biology2025

Basal forebrain volume is associated with cortical amyloid burden in cognitively unimpaired older adults at varying genetic risk for Alzheimer's disease.

Gawon Cho, Kaitlin Kelly, Takuya Toyonaga, Richard E Carson, Brienne Miner, Joel Gelernter, Pradeep Varma, Christopher H van Dyck, Adam P Mecca, Ryan O'Dell

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Gawon ChoDepartment of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.ORCID 0000-0002-3512-8982
Kaitlin KellyYale Alzheimer's Disease Research Unit, Yale School of Medicine, New Haven, CT, USA.
Takuya ToyonagaDepartment of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT, USA.ORCID 0000-0002-0369-8294
Richard E CarsonDepartment of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT, USA.
Brienne MinerDepartment of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
Joel GelernterDepartment of Psychiatry, Yale School of Medicine, New Haven, CT, USA.ORCID 0000-0002-4067-1859
Pradeep VarmaDepartment of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT, USA.
Christopher H van DyckYale Alzheimer's Disease Research Unit, Yale School of Medicine, New Haven, CT, USA.
Adam P MeccaYale Alzheimer's Disease Research Unit, Yale School of Medicine, New Haven, CT, USA.
Ryan O'DellYale Alzheimer's Disease Research Unit, Yale School of Medicine, New Haven, CT, USA.

Funding

Yale Study Support Suite (YES3): Dashboard and Web Portal Software Supporting Research Workflow through integrated, customizable REDCap External ModulesP30AG021342 · NIA · YALE UNIVERSITY · PI Albert C Shaw · 2002 to 2026
$37.9M
Yale Alzheimer Disease Research CenterP30AG066508 · NIA · YALE UNIVERSITY · PI STEPHEN M STRITTMATTER, CHRISTOPHER H VAN DYCK · 2020 to 2026
$30.2M
PET Imaging of SV2A and Other Biomarkers in Alzheimer's DiseaseR01AG062276 · NIA · YALE UNIVERSITY · PI VAN DYCK, CHRISTOPHER H · 2018 to 2022
$5.5M
PET Imaging of Synaptic Density in Alzheimers DiseaseR01AG052560 · NIA · YALE UNIVERSITY · PI CARSON, RICHARD E., VAN DYCK, CHRISTOPHER H · 2017 to 2020
$3.2M
Investigation of molecular changes in mGluR5 and SV2A to study synaptic alterations in Alzheimer's disease using PET.K23AG057794 · NIA · YALE UNIVERSITY · PI MECCA, ADAM PETER · 2018 to 2022
$977k
NIA NIH HHS K23 AG057794NIA NIH HHS P30 AG021342NIA NIH HHS P30 AG066508NIA NIH HHS R01 AG052560NIA NIH HHS R01 AG062276
6 · The paper itself

Abstract

Background: In mild cognitive impairment and dementia due to Alzheimer's disease (AD), postmortem and Methods: Cognitively unimpaired participants aged 50-65 with a first-degree family history for AD were genetically screened to select three groups: Results: BFCS amyloid burden was highest among Conclusions: We observed nbM (Ch4), but not MTL volume, to be significantly inversely associated with cortical amyloid burden in cognitively unimpaired, Aβ+, middle-aged adults at varying genetic risk for AD. These findings provide further in vivo evidence suggesting that nbM atrophy is an early structural correlate of AD pathogenesis, potentially preceding MTL atrophy.

Identifiers

PMID40501985
PMCPMC12154762

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.